Cover Image
市場調查報告書

高度惡性神經膠質瘤的開發中產品分析

High-Grade Glioma - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 271830
出版日期 內容資訊 英文 159 Pages
訂單完成後即時交付
價格
Back to Top
高度惡性神經膠質瘤的開發中產品分析 High-Grade Glioma - Pipeline Review, H2 2015
出版日期: 2015年12月16日 內容資訊: 英文 159 Pages
簡介

高度惡性神經膠質瘤(HGG)是中樞神經系統(CNS)的腫瘤,發病於腦·脊椎的惡性轉換細胞。主要的症狀為發育遲緩和頭痛·背痛、噁心·嘔吐、暈眩、步行障礙、視力降低、集中力降低、睡意、睡眠障礙、不規則的食慾、麻痺·癲癇等。主要的治療方法有化療和放射治療等。

本報告提供全球各國治療量等級神經膠質瘤(Glioma)用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

高度惡性神經膠質瘤(Glioma)概要

治療藥的開發

  • 高度惡性神經膠質瘤開發中產品:概要
  • 高度惡性神經膠質瘤開發中產品:比較分析

各企業開發中的高度惡性神經膠質瘤治療藥

大學/研究機關研究中的高度惡性神經膠質瘤治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

高度惡性神經膠質瘤治療藥:開發中的產品一覽(各企業)

高度惡性神經膠質瘤治療藥:研究中的產品一覽(大學/研究機關別)

高度惡性神經膠質瘤治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Bayer AG
  • Virttu Biologics Limited
  • AngioChem Inc.
  • Stemline Therapeutics, Inc.
  • TAU Therapeutics, LLC
  • Tocagen Inc.
  • AROG Pharmaceuticals LLC

高度惡性神經膠質瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • nintedanib
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ANG-1005
  • ANG-1005
  • (dabrafenib + trametinib)
  • Gene Therapy for High-Grade Glioma and Liver Transplantation
  • Dendritic Cell Vaccine
  • sorafenib tosylate
  • vocimagene amiretrorepvec + flucytosine ER
  • SL-701
  • crenolanib besylate
  • mibefradil dihydrochloride
  • GDC-0084
  • HSV-1716
  • TBX-01
  • Toca- RNAi

高度惡性神經膠質瘤治療藥:開發中產品的最新趨勢

高度惡性神經膠質瘤治療藥:暫停開發的產品

高度惡性神經膠質瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7463IDB

Summary

Global Markets Direct's, 'High-Grade Glioma - Pipeline Review, H2 2015', provides an overview of the High-Grade Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for High-Grade Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High-Grade Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of High-Grade Glioma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for High-Grade Glioma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the High-Grade Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the High-Grade Glioma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for High-Grade Glioma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding High-Grade Glioma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High-Grade Glioma Overview
  • Therapeutics Development
    • Pipeline Products for High-Grade Glioma - Overview
    • Pipeline Products for High-Grade Glioma - Comparative Analysis
  • High-Grade Glioma - Therapeutics under Development by Companies
  • High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes
  • High-Grade Glioma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • High-Grade Glioma - Products under Development by Companies
  • High-Grade Glioma - Products under Investigation by Universities/Institutes
  • High-Grade Glioma - Companies Involved in Therapeutics Development
    • AngioChem Inc.
    • Arog Pharmaceuticals, Inc.
    • Bayer AG
    • Boehringer Ingelheim GmbH
    • Cavion LLC
    • Kinex Pharmaceuticals, LLC
    • Merrimack Pharmaceuticals, Inc.
    • Millennium Pharmaceuticals, Inc.
    • Nektar Therapeutics
    • Novartis AG
    • Oncolytics Biotech Inc.
    • Sanofi
    • Stemline Therapeutics, Inc.
    • Targepeutics, Inc.
    • Tocagen Inc.
    • Virttu Biologics Limited
  • High-Grade Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Gliomas - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etirinotecan pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GB-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HSV-1716 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KX-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • nintedanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel trevatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pelareorep - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plerixafor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SL-701 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Toca-Gamma - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Toca-RNAi - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vocimagene amiretrorepvec + flucytosine ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • High-Grade Glioma - Recent Pipeline Updates
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
      • May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
      • May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin -Refractory High-Grade Glioma Presented at 50th ASCO Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for High-Grade Glioma, H2 2015
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • High-Grade Glioma - Pipeline by AngioChem Inc., H2 2015
  • High-Grade Glioma - Pipeline by Arog Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Bayer AG, H2 2015
  • High-Grade Glioma - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • High-Grade Glioma - Pipeline by Cavion LLC, H2 2015
  • High-Grade Glioma - Pipeline by Kinex Pharmaceuticals, LLC, H2 2015
  • High-Grade Glioma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2015
  • High-Grade Glioma - Pipeline by Novartis AG, H2 2015
  • High-Grade Glioma - Pipeline by Oncolytics Biotech Inc., H2 2015
  • High-Grade Glioma - Pipeline by Sanofi, H2 2015
  • High-Grade Glioma - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Targepeutics, Inc., H2 2015
  • High-Grade Glioma - Pipeline by Tocagen Inc., H2 2015
  • High-Grade Glioma - Pipeline by Virttu Biologics Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • High-Grade Glioma Therapeutics - Recent Pipeline Updates, H2 2015
  • High-Grade Glioma - Dormant Projects, H2 2015
  • High-Grade Glioma - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for High-Grade Glioma, H2 2015
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top